Healthcare Review: Dara BioSciences, Vivus, Array BioPharma, Retrophin, Valeant Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Wednesday, 28 May 2014 12:54
U.S. stocks slipped, with technicals in focus and scant key items on the U.S. economic calendar, as the S&P 500 hit yet another intraday record in early trading Wednesday. Investors' appetite for equities has been supported by recent strong U.S. economic data and expectations of monetary easing by the European Central Bank, while the U.S. 10-year yield touched its lowest since July, below 2.46 percent.

Shares of thinly-traded pico cap Dara BioSciences ($DARA) explode on massive turnover despite no news. On a technical basis, the stock has been on a significant downtrend since its January 22 high of $4.40 bottoming at $1.02 on May 19. It has lost over 99.9% of its value since 2007 so retail investors need to be careful here.

Shares of Vivus ($VVUS) are up on heavy volume on rumors that Aspen Investment Plans is considering a $640M bid for the company.

Array BioPharma ($ARRY) and Biogen Idec ($BIIB) sign a collaboration agreement for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders that were discovered through ARRY's Kinase-Directed Phenotypic Screening Platform. Under the terms of the agreement, BIIB will be responsible for all aspects of clinical development and commercialization and will fund research for three years. ARRY will be eligible for certain development and commercial milestone payments and royalties on top-line sales.

Retrophin ($RTRX) appoints Stephen Aselage President and COO effective immediately. He will be responsible for corporate development activities including the commercialization of current products, building out the firm's global infrastructure and exploring new business development opportunities.

Valeant Pharmaceuticals ($VRX) increases its bid for Allergan ($AGN). Its new offer is now $58.30 in cash (an increase of ~21%), 0.83 VRX share, one contingent value right (CVR) related to DARPin sales (worth ~$25/share based on $20B cumulative sales over 10 years) and a commitment to invest up to $400M in DARPin while retaining current AGN employees responsible for development.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter